Dupilumab (Dupixent®) is indicated for treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||13/11/2017|
|Rapid review completed||24/11/2017|
|Rapid Review outcome||Full pharmacoeconomic assessment recommended|
|Full pharmacoeconomic assessment commissioned by the HSE||29/11/2017|
|Pre-submission consultation with Applicant||18/06/2018|
|Current Status||Awaiting Applicant submission|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.